

Prevalence and Management of Treatment-Resistant Depression

Charles B. Nemeroff, M.D., Ph.D.

Treatment-resistant depression (TRD) is a major public health problem in terms of its prevalence and in terms of individual suffering and cost to society. Best estimates indicate 12-month prevalence rates of ~3% for Stage 1 TRD (failure to respond to 1 adequate trial of an antidepressant) and ~2% for Stage 2 TRD (failure to respond to 2 adequate trials). The current article provides a brief review of the definitions, prevalence, and various treatment options for TRD, including switching, augmentation, and combination therapies and use of nonpharmacologic treatments. Given the public health importance of TRD, the relative absence of adequately powered, double-blind trials is striking.

(*J Clin Psychiatry* 2007;68[suppl 8]:17–25)

The traditional definition of *treatment-resistant depression* (TRD) requires an inadequate response to an adequate course of treatment in a patient meeting criteria for major depressive disorder (MDD). In the past decade, almost all parts of this traditional definition have been subjected to scrutiny and have had empirical criteria applied to them. *Inadequate response* has been operationalized by applying specific criteria for treatment response or, alternatively, remission. The magnitude of TRD increases substantially if failure to achieve remission is used as the qualifying criterion. However, although remission is the gold standard outcome for antidepressant treatment, failure to achieve remission is not typically required for a patient to meet criteria for TRD.

What constitutes an *adequate course of treatment* has been operationalized relatively recently by delineating a TRD staging system (Table 1).¹ Criteria for Stage 1 and 2 TRD require failure to respond, respectively, to 1 or 2 adequate antidepressant trials. Each trial must comprise antidepressants of distinctly different classes. Stage 3 requires a third trial which must include a course of treatment with a tricyclic antidepressant, if this class was not used in Stage 1 or 2. Stage 4 TRD requires failure to respond to at least 4 different classes of antidepressants, one of which must be a monoamine oxidase inhibitor. Stage 5 TRD requires meeting all Stage 4 criteria, in addition to which a patient must have failed an adequate course of electroconvulsive therapy (ECT).

Treatment-resistant depression typically is limited to patients who meet criteria only for unipolar MDD. There is

no consensus as to whether patients with extensive and/or severe Axis I comorbidity should be categorized as having TRD. Additional research is needed to characterize the extent to which TRD might be secondary to untreated comorbid disorders such as anxiety syndromes or other Axis I disorders, Axis II diagnoses, or medical illness.

More research is also needed to refine the TRD staging system, which, at this point, continues to be largely a proposed schema. Issues which need to be addressed include (1) Is response, remission, or complete recovery a more clinically useful outcome criterion? (2) Should each antidepressant treatment have a different mechanism of action? (3) Should combined therapies or treatment augmentation be included in staging? (4) Should newer treatments (e.g., vagal nerve stimulation) be included in the staging schema? (5) How should Axis I comorbidity be handled? (6) Are all symptom response or remission criteria (e.g., using HAM-D ≤ 6) created equal? In other words, taking remission as an example, does the presence of single symptoms rated as “severe” (such as insomnia or hopelessness/suicidality) have the same prognostic significance as multiple symptoms rated as “mild”?

Another important question is whether Stage 4 or 5 TRD might not constitute a unique depressive subtype.² It would not be surprising if failure to respond to multiple adequate antidepressant trials, which typically target monoaminergic neurotransmitters, might define a unique pathophysiologic subgroup. Pharmacogenomic and functional imaging studies are needed to clarify this issue.

PREVALENCE OF TRD

Given the lack of consensus criteria, it is perhaps not surprising that no agreed-upon estimates of the prevalence of TRD exist. It follows from the TRD staging schema, summarized above, that the prevalence of TRD is not a unitary phenomenon. Instead, different prevalence rates will be associated with each TRD stage. Estimates of TRD prevalence also vary greatly depending on the treatment setting in which

From the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga.

Based in part on a presentation from an expert consensus roundtable entitled “MAOIs Revisited: Their Role in Depressive Disorders,” held in Miami, Fla., on Jan. 29, 2006, and supported by an educational grant from Bristol-Myers Squibb Company.

Financial disclosure for Dr. Nemeroff is listed at the end of the article.

Corresponding author and reprints: Charles B. Nemeroff, M.D., Ph.D., Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA (cnemero@emory.edu).

Table 1. Thase-Rush Treatment-Resistant Depression (TRD) Staging Method^a

TRD Stage	Criteria
Stage 1	Failure of an adequate trial of 1 class of major antidepressant
Stage 2	Failure of adequate trials of 2 distinctly different classes of antidepressants
Stage 3	Stage 2 plus failure of a third class of antidepressant, including a tricyclic antidepressant
Stage 4	Stage 3 plus failure of an adequate trial of a monoamine oxidase inhibitor
Stage 5	Stage 4 plus failure of an adequate course of electroconvulsive therapy

^aAdapted with permission from Thase and Rush.¹

the estimate is made, with the lowest rates expected in primary care settings, and progressively higher rates occurring in outpatient psychiatry settings, inpatient psychiatric settings, and academic/tertiary care settings.

On the basis of data from randomized controlled trials (RCTs) conducted in a research setting, Stage 1 TRD has been reported to have a prevalence of ~50% when “response” is used as the criterion outcome and at least 60% when “remission” is used.^{3,4} Studies conducted in clinical practice settings have reported even lower remission rates, in the range of 15% to 35%.^{5,6} In the National Institute of Mental Health (NIMH)–sponsored Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, which was conducted in both psychiatric and primary care practice settings, patients with nonpsychotic major depression (N = 2876) were treated in Stage 1 for 12 weeks with citalopram at a mean final daily dose of 55 mg. Stage 1 response rates were 47% and remission rates were 28%.⁷ These findings would suggest a prevalence for Stage 1 TRD of ~50% using response criteria and of ~70% using remission criteria.

Recent STAR*D data reported response rates of 26% to 28% when switching to a second antidepressant (sustained-release bupropion [N = 239], sertraline [N = 238], or venlafaxine-XR [N = 250]) after failure to achieve remission (or intolerance) with initial citalopram treatment.⁸ Alternatively, combination of an SSRI with sustained-release bupropion (N = 279) was associated with a 32% response rate.⁹ If one extrapolates from STAR*D data, then Stage 2 TRD (failure to achieve response criteria after 2 courses of adequate treatment) may be estimated to occur in approximately 35% of patients. Given a 12-month MDD prevalence estimated at 6.6%,¹⁰ then the total 12-month prevalence estimates are ~3% for Stage 1 TRD and ~2% for Stage 2 TRD. Adequately powered and well-controlled trials of TRD in Stages 3 to 5 in clinical practice settings have not been reported, and thus no estimates are available.

An alternative TRD staging model has been proposed that uses a scoring system in which points are assigned depending on the type of adequate trial(s) that the patient has failed to respond to, and that takes into account whether the trials

have been optimized in terms of higher doses and/or longer durations and/or use of augmentation.¹¹ A retrospective chart review of the treatment histories of 115 patients diagnosed with MDD found the alternative TRD scoring system and the STAR*D scoring system to be highly correlated, although the former had higher predictive validity.¹²

COSTS AND BURDEN OF TRD

Treatment-resistant depression is a costly illness that is associated with a significant increase in both medical and psychiatric health care costs. Compared to non-TRD, TRD patients have been reported to have significantly higher outpatient medical costs and to be approximately twice as likely to be hospitalized, either medically or psychiatrically.^{12,13} Patients with TRD who were hospitalized had a 6-fold increase in overall medical costs compared to non-TRD patients (\$42,344 vs. \$6512).¹²


Treatment-resistant depression also is thought to be associated with a significant increase in indirect costs (e.g., lost work and decreased productivity) for both identified patients and family members. However, accurate estimates of TRD-related indirect costs are not available. For non-TRD, the proportion of the total cost burden contributed by indirect costs is approximately 2-times the proportion contributed by direct medical costs.¹⁴

CORRELATES AND PREDICTORS OF TRD

Although various clinical and demographic factors have been identified that are associated with an increased risk of treatment nonresponse (see below), it is important to note that more than half of treatment nonresponse in MDD appears to be due to 2 factors: (1) poor adherence to prescribed treatments and (2) poor tolerability. Poor tolerability may result in nonadherence, but is only one of several causes.

The extent to which poor adherence and/or poor tolerability contribute to treatment-resistance is uncertain, especially because the tolerability and adherence rates in classic placebo-controlled efficacy trials do not generalize well to “real world” clinical settings.¹⁵ Overall, it has been estimated that up to 20% of TRD might be attributable to nonadherence.¹⁶ However, this is likely to be a significant underestimate, because usual care data from primary care settings indicate that only ~40% of patients take adequate antidepressant dosages during the first 6 months of treatment.⁶ Nonadherence has been most commonly associated with younger age and intolerance of adverse events.¹⁷ In the STAR*D program, maximum side effect intensity was rated as “severe-intolerable” after a course of acute treatment by 10% of patients who achieved remission and by 18% of patients who did not.⁷ Among successful remitters, the likelihood that treatment will be continued, and remission maintained, over many months is unlikely in the presence of severe-intolerable side effects.

Figure 1. Factors to Consider in Patients Failing First Trial of Antidepressant Monotherapy



FAILURE AFTER 1 COURSE OF TREATMENT: DIFFERENTIAL DIAGNOSIS OF TRD STAGE 1

More than one third of patients who complete an initial course of antidepressant treatment will not achieve a satisfactory response, and at least two thirds will not achieve remission. These patients qualify for Stage 1 TRD. The likelihood that they will progress to Stage 2 TRD may be reduced substantially by systematically reviewing the common reasons for treatment failure (Figure 1).

First, it is important to confirm that the prescribed dose of antidepressant was adequate and was taken for a sufficient duration. The overall dose-response curve is relatively flat for SSRIs within their therapeutic dosing range, but some patients clearly benefit from taking higher doses. Other classes of antidepressants (e.g., tricyclics, and perhaps serotonin-norepinephrine reuptake inhibitors [SNRIs]) exhibit a more significant dose-response curve.¹⁸ Similarly, 6 weeks of treatment appears to be an adequate duration for the majority of patients, but there is a subgroup of patients who may benefit from a longer course of treatment. The following variables have been identified as risk factors for delayed remission: chronicity (both duration of the current episode and number of previous episodes), older age, the presence of psychiatric and medical comorbidity, and symptom severity.^{1,19,20} Treatment optimization (higher doses and/or additional weeks of treatment) is one option, especially when the treatment response is suboptimal, i.e., insufficient to qualify as remission.

A second important consideration, as noted in the previous section, is whether the patient has been compliant with the prescribed regimen. Studies suggest that approximately one third of patients are nonadherent to prescribed antidepressant regimens.¹⁵ If medication nonadherence is due to poor tolerability, then alternative antidepressants may need to be prescribed.

A third important consideration is to review the diagnosis—both the primary diagnosis and the presence of comorbid diagnoses. Does the patient suffer from a subtype of MDD (e.g., bipolar, psychotic, atypical) that might benefit from use of another class of antidepressant, or some

combination therapy, or ECT? The article by Rush in the current issue²¹ reviews the treatment implications of depression subtypes.

In addition to MDD subtype, it is important to evaluate whether the diagnosis of MDD is complicated by comorbid medical or psychiatric illnesses. In the STAR*D program, significant medical comorbidity was present in 53% of patients and was more likely to occur in older patients, in patients with lower socioeconomic and educational status, and in patients with no family history of depression.²² All patients, particularly those with TRD, should be evaluated for comorbid medical illness (or medication treatment) that might be contributing to the depression, or interfering with its successful treatment.

Clinically relevant comorbid psychiatric illness is also very common and is also likely to contribute to treatment resistance. Psychiatric comorbidity in MDD is significantly higher if the patient is younger, female, and of lower socioeconomic status.²³ In a multivariate regression model, the STAR*D program identified obsessive-compulsive disorder (odds ratio [OR], 0.71) and posttraumatic stress disorder (OR, 0.63) as the only significant independent predictors of incomplete treatment response.⁷ In univariate logistic regression analyses, incomplete response was also predicted by generalized anxiety disorder (0.80), panic disorder (0.62), agoraphobia (0.64), and somatoform disorder (0.40). Interestingly, alcohol and substance dependence/abuse were not negative predictors of response; nor was social anxiety disorder or bulimia. Current comorbidity was relatively common between MDD and generalized anxiety disorder (24%), obsessive-compulsive disorder (14%), panic disorder (13%), and posttraumatic stress disorder (21%). Overall, 76% of patients had at least 1 current comorbid disorder, and 38% had 2 or more. The odds of achieving a complete response progressively decreased as a function of the number of comorbidities, from 1 (OR, 0.83) to 4 or more (OR, 0.52).

If treatment nonresponders are suffering from concurrent Axis I comorbidity, then the specific comorbidity may be a useful guide in choosing which drug or combination of drugs might be most efficacious. Despite the appeal of this approach, there are surprisingly few double-blind RCTs that compare the effectiveness of 2 antidepressants, or combination therapy, in treating MDD with current Axis I comorbidity.

MANAGEMENT OPTIONS FOR TRD

Switching

In the past 5 years, the great majority of patients diagnosed with MDD receive either a selective serotonin reuptake inhibitor (SSRI) or SNRI antidepressant as their first course of treatment. If the first trial fails to achieve an adequate response, and no specific reason can be identified and corrected (as summarized above), then switching to a second antidepressant is the most common next step.

A large number of open-label trials^{24–33} and a few double-blind, controlled trials^{34–38} suggest that such switching is effective in achieving a response in approximately 40% to 60% of cases. It is frequently recommended that patients who fail one class of antidepressant be switched to a class of antidepressant with a different mechanism of action. Even though the recommendation appears to have merit, to date, there is no good evidence that between-class switching increases the likelihood of achieving either response or remission compared to within-class switching.

Recently reported results from the STAR*D also do not support any advantage for between-class switching.⁸ Patients who failed to respond to citalopram had similar response rates after within-class switching to sertraline (27%) when compared to between-class switching to either sustained-release bupropion (26%) or extended-release venlafaxine (28%). The relatively low rates of treatment response for all 3 second-line treatments are somewhat disappointing, especially for venlafaxine-XR with its dual serotonin and norepinephrine reuptake inhibiting action. Of interest, within-class switching to sertraline was well-tolerated, even in the subgroup of patients who reported poor tolerability to their initial course of treatment with citalopram. It is important to note that although citalopram and sertraline share the property of blockade of serotonin reuptake, they also have unique pharmacologic properties. Thus, sertraline is a relatively potent dopamine reuptake inhibitor.³⁹

Monoamine oxidase inhibitor (MAOI) antidepressants have long been considered a treatment option in patients with TRD,⁴⁰ and use of an MAOI is one of the treatment options in TRD staging.¹ Several clinical trials and retrospective chart reviews suggest that the classic MAO inhibitors (tranylcypromine and phenelzine) have efficacy in both early and late stage TRD.^{34,35,41–48} The third conventional MAOI, isocarboxazid, has not been studied in this regard. The results of these studies suggest that approximately 50% of patients meeting criteria for TRD, including Stages 2 and 3, will respond to treatment with either tranylcypromine or phenelzine. Larger and more methodologically rigorous RCTs are needed to establish the place of MAOIs in the emerging TRD treatment algorithm.

Safety concerns with first-generation MAOIs, specifically the potential for a hypertensive crisis, have limited research on this class of drugs, as well as the willingness of physicians and patients to use the drugs in clinical practice, even among TRD patients. The greater safety of the new MAOI selegiline, administered transdermally, may reverse this reluctance; however, before this can happen, much research needs to be done to establish its efficacy in TRD.

Augmentation/Combination Therapy

A survey of prescribing practices found that raising the dose was the most common “next-step” when patients achieved a partial response, followed by augmentation.⁴⁹

Table 2. Drugs Used for Augmentation in Treatment-Resistant Depression (TRD)^a

Drug	Strength of Evidence of Efficacy in TRD
Lithium	A (with TCA) C (with SSRI)
Bupropion or mirtazapine combination therapy	B
Anticonvulsants (lamotrigine, divalproex sodium, carbamazepine)	B
Thyroid hormone (T ₃)	B (with TCA) C (with SSRI)
Atypical antipsychotics (risperidone, olanzapine, ziprasidone, aripiprazole)	B (olanzapine) C (other atypicals)
Dopamine agonists (pramipexole)	C
Pindolol	C
Stimulants	C
Buspirone	B
Modafinil	B/C
Testosterone, estrogen	C
Miscellaneous (buprenorphine, SAMe, inositol)	C

^aData from Thase.¹¹¹

A: ≥ 2 adequately powered, double-blind, placebo-controlled trials.

B: ≥ 1 adequately powered, double-blind, placebo-controlled trial (or an equivalent weight of evidence from multiple smaller trials).

C: positive evidence from open-label trials and case series.

Abbreviations: SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressants.

This inclination to raise the dose is perhaps unfortunate, because surveys suggest that dose escalation as a treatment strategy may not be particularly effective in patients being treated with SSRIs.⁴⁹ For nonresponse, augmentation is the most common “next-step” after switching to a non-SSRI antidepressant.^{49,50}

A wide array of drugs have been used to augment the efficacy of antidepressants in patients with various stages of TRD (Table 2). Surveys suggest that choice of augmentation strategy among clinicians is fairly evenly divided among 4 categories: (1) bupropion, (2) dual-acting combinations (serotonin/norepinephrine), (3) lithium, and (4) miscellaneous agents including triiodothyronine (T₃), buspirone, pindolol, psychostimulants, etc.

Evidence for the benefit of bupropion in TRD rests upon uncontrolled case reports and pilot data,⁵¹ and the recently reported STAR*D results.⁸ In the STAR*D study, remission rates were modestly higher after augmentation with sustained-release bupropion (39%) compared to buspirone (33%). In addition, bupropion was better tolerated than buspirone, with significantly lower attrition due to adverse events (12% vs. 21%). This latter finding confirms the clinical practice perception of the favorable tolerability of bupropion in combination therapy. It should be noted that the STAR*D data examined early stage TRD. The efficacy of bupropion as an augmentation strategy in late stage TRD is unproven.

Use of dual-action antidepressants as an augmentation strategy may be accomplished by combining an SSRI with a noradrenergic reuptake inhibitor (atomoxetine, desipramine) or switching to (or adding) duloxetine or venlafaxine-XR. Alternatively, treatment with an SSRI or SNRI has been

augmented with α_2 -adrenergic antagonists such as mirtazapine or mianserin (not available in the United States). As noted above, combining drugs to achieve a dual action is one of the most common augmentation strategies. Available studies that test this augmentation strategy show promising results,⁵²⁻⁵⁴ but it is important to note that there are virtually no adequately powered, double-blind, placebo-controlled trials available in well-defined TRD. One of the largest double-blind trials tested the comparative efficacy of using a dual-action agent (venlafaxine) and simple switching to another SSRI (paroxetine) in TRD.⁵⁵ Treatment with venlafaxine resulted in significantly higher remission rates than paroxetine (N = 122; 42% vs. 20%).

Lithium and T₃ are 2 commonly used augmentation strategies that predate the introduction of SSRI and SNRI antidepressants. Meta-analyses of multiple studies, mostly poorly designed and notably underpowered, have found the use of T₃ augmentation to be associated with a significant increase in the likelihood of response and in the speed of response to antidepressants.^{56,57} Only a small subsample of these patients met criteria for TRD. After almost 50 years of use of T₃ as an augmentation strategy in depression, the quality of the evidence for T₃ augmentation is poor, despite the promising nature of the results.

The use of lithium as an augmentation strategy in TRD is almost as venerable as T₃ use. A recent meta-analysis identified 27 studies with a total of 803 patients.⁵⁸ Once again, the majority of the studies were open-label and/or used no placebo control. TRD staging was imprecise and the antidepressant therapy that was being augmented was highly heterogeneous, even within a given study. Overall, 10 double-blind, placebo-controlled studies were identified, but all were notably underpowered, with sample sizes per treatment group ranging from N = 3 to a high of N = 30. In the placebo-controlled trials, the response rate was significantly higher with lithium augmentation (45%) than with placebo (18%).

A recently published STAR*D study⁵⁹ compared the efficacy of augmentation with lithium (N = 69; 900 mg/day) or T₃ (N = 73; up to 50 μ g/day) in patients diagnosed with nonpsychotic MDD who had failed 12 weeks of prospective treatment with both citalopram and a second course of treatment that consisted of either switching to a second antidepressant class or augmentation with bupropion or buspirone. After 10 weeks of treatment, remission rates were 16% with lithium augmentation and 25% with T₃ augmentation. The efficacy advantage in favor of T₃ was not significant, although T₃ augmentation was significantly better tolerated.

Miscellaneous other augmentation strategies have been employed, including pindolol, atypical antipsychotics, anticonvulsants, dopaminergic agents, estrogen, testosterone, and multiple other agents (buprenorphine, SAMe, inositol).

Pindolol is a β -blocker with presynaptic 5-HT_{1A} antagonist activity that has shown promise as an agent for optimizing antidepressant response in non-treatment-resistant

patients. However, a series of small controlled trials of its use as an augmentation strategy in TRD have been negative, although the doses employed may have been inadequate.⁶⁰⁻⁶²

Atypical antipsychotics have been suggested as augmentation agents in TRD because they act on a wide range of receptor targets that may have antidepressant effects, such as antagonist activity at 5-HT_{2A} receptors. A flurry of research studies have been published in the past 5 years that examine the use of atypical antipsychotics as an augmentation strategy in (nonpsychotic) TRD.⁶³⁻⁷² The results are very promising, although it should be noted that many of the available studies are open-label or underpowered double-blind trials. To date, only 2 large, double-blind trials^{65,72} have been reported. In the first study,⁶⁵ similar response and remission rates, respectively, were reported after 8 weeks of double-blind treatment with combined olanzapine/fluoxetine (28%, 17%), compared to monotherapy with olanzapine (19%, 13%), fluoxetine (29%, 13%), or nortriptyline (30%, 18%). In the second study,⁷² the long-term relapse prevention benefits were examined when risperidone was combined with citalopram in citalopram nonresponders who had shown an initial response to risperidone augmentation. Even though initial open-label augmentation was highly effective in achieving an initial response (63%), a double-blind comparison of continuation therapy with citalopram plus placebo versus citalopram plus risperidone found no additional relapse prevention benefit from combined use of risperidone on the primary outcome measure, though secondary outcome measures favored the combination.

Anticonvulsants, especially lamotrigine, have been used as augmentation agents, in both treatment-resistant unipolar and bipolar depression. Preliminary studies suggest potential benefit, but adequate controlled trials are not yet available.^{73,74}

Various dopaminergic agents, including psychostimulants, bromocriptine, pergolide, ropinirole, and pramipexole, have been used to augment the efficacy of antidepressants. Psychostimulants, such as dextroamphetamine and methylphenidate, have been used clinically for many years. The antidepressant effects occur rapidly, but have been reported to be transient. Data on the potential benefits and risks of psychostimulants in TRD come exclusively from small case series and open-label studies.⁷⁵⁻⁷⁹ No double-blind, placebo-controlled trials are available in TRD.

More recently, modafinil has been studied in patients with partial or nonresponse to SSRI or SNRI antidepressants. Modafinil is a stimulant-like medication with a novel mechanism of action that is not fully understood, but appears to differ from amphetamine-type drugs. Modafinil has shown promise as an augmentation agent in Stage I TRD by targeting unresponsive depressive symptoms such as fatigue, lack of energy, and poor concentration.⁸⁰⁻⁸⁴

Pramipexole is a novel D_{2/3} agonist that has been suggested as a potential augmentation agent based on efficacy

results obtained in a series of pilot studies (some randomized and with a placebo control) of bipolar depression, including treatment-resistant patients.^{85–89} Currently no RCTs of pramipexole are available that evaluate its efficacy of TRD.

Nonpharmacologic Therapy

Six somatic, nonpharmacologic treatments of TRD have been studied: ECT, vagus nerve stimulation, transcranial magnetic stimulation, deep brain stimulation, magnetic seizure therapy, and cognitive-behavioral therapy.

Electroconvulsive therapy is the best-studied and most effective single treatment for advanced TRD. Meta-analyses performed over the past 20 years consistently find ECT to have a larger effect size than other classes of antidepressants, including tricyclic antidepressants, MAO inhibitors, and SSRI and SNRI antidepressants.^{90–92} The few studies that have directly compared the efficacy of ECT to pharmacologic treatment have found higher response rates with ECT.⁹³

Vagus nerve stimulation (VNS) therapy is delivered by a pocket watch–sized device that is implanted in the left chest wall and that is connected to the left vagus nerve by electrodes in the neck. The VNS device is approved by the U.S. Food and Drug Administration for both refractory epilepsy and TRD. VNS is hypothesized to act, via ascending projections, by altering the activity of CNS regions implicated in MDD (e.g., orbital frontal cortex, insula, thalamus, hypothalamus, cingulate, and hippocampus).^{94–96} VNS treatment has been shown to increase the CNS concentration of 5-HIAA, homovanillic acid, and GABA.⁹⁷ VNS has demonstrated significant efficacy in an open trial of TRD,⁹⁸ as well as in 2 short-term, double-blind trials, one evaluating VNS as a monotherapy, and one study evaluating VNS in combination with usual treatment with antidepressants.^{99–101}

Repetitive transcranial magnetic stimulation (rTMS) is a neurostimulatory therapy in which a pulsed electromagnetic field is applied to the left prefrontal cortex. rTMS has shown modest-to-moderate efficacy in MDD.¹⁰² Well-designed RCTs of rTMS employ a double-blind, sham rTMS control group. Active treatment consists of high-frequency rTMS (between 5–20 Hz) applied to the left dorsolateral prefrontal cortex.

Recently, 3 small but well-designed trials have all demonstrated significant antidepressant response to rTMS in patients meeting criteria for TRD.^{103–105} Response rates for rTMS are ~30%, in the same range as reported for switching in the STAR*D program. These preliminary results strongly suggest a role for rTMS in the treatment of TRD, but confirmation of the potential benefit of rTMS awaits the publication of a large, well-controlled RCT.¹⁰⁶

Magnetic seizure therapy uses the same machine as is used for rTMS therapy, but the pulsed magnetic field is used to produce focal stimulation sufficient to trigger a seizure. Thus, magnetic seizure therapy is a variant of ECT. It has been studied only in 1 pilot study and in a case series.^{107,108}

It appears to be better tolerated than ECT, but whether it will have comparable efficacy awaits the results of ongoing controlled trials.

A more recent neurostimulatory treatment approach uses deep brain stimulation to treat severe and intractable TRD. Deep brain stimulation has been reported to be effective in pilot studies, but controlled trials with adequate follow-up are needed.^{107,109}

Finally, psychotherapy, especially cognitive-behavioral therapy, has been suggested as a nonpharmacologic approach to TRD, especially Stage 1 or Stage 2. While psychosocial problems are prominent complications of TRD, no large controlled trials of psychotherapy in TRD have been reported.¹¹⁰

CONCLUSIONS

This brief review of TRD highlights the importance of 2 specific issues. First, TRD is a major, and relatively neglected, public health issue, with an estimated 12-month prevalence of ~3% for Stage 1 resistance and ~2% for Stage 2. Second, given the prevalence of TRD and the magnitude of the public health problem it represents, what is striking about TRD is the relative dearth of adequately powered, randomized, double-blind treatment studies. Currently, there are more than 2 dozen TRD treatment strategies, all supported by (often multiple) open-label trials, case series, and small double-blind pilot studies. Promising pilot studies are rarely followed up by well-designed trials that rigorously test a candidate treatment.

Finally, the fascination with novel TRD treatment strategies appears to have distracted us from focusing on the prosaic fact that optimizing treatment adherence and careful diagnosis to identify and target medical and psychiatric illnesses that are comorbid with TRD may have as high a yield in overall response as the next novel drug.

Drug names: aripiprazole (Abilify), atomoxetine (Strattera), bromocriptine (Parlodel and others), buprenorphine (Buprenex, Subutex, and others), bupropion (Wellbutrin and others), buspirone (BuSpar and others), carbamazepine (Tegretol, Eptol, and others), citalopram (Celexa and others), desipramine (Norpramin and others), dextroamphetamine (Dexedrine, Dextrostat, and others), divalproex sodium (Depakote), duloxetine (Cymbalta), fluoxetine (Prozac and others), fluoxetine-olanzapine (Symbyax), isocarboxazid (Marplan), lamotrigine (Lamictal and others), lithium (Eskalith, Lithobid, and others), methylphenidate (Daytrana, Ritalin, and others), mirtazapine (Remeron and others), modafinil (Provigil), nortriptyline (Pamelor and others), olanzapine (Zyprexa), paroxetine (Paxil, Pexeva, and others), pergolide (Permax and others), phenelzine (Nardil), pindolol (Visken and others), pramipexole (Mirapex), risperidone (Risperdal), ropinirole (Requip), selegiline (Emsam, Eldepryl, and others), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others), ziprasidone (Geodon).

Financial disclosure: At the time of this roundtable consensus conference, Dr. Nemeroff was a consultant for Abbott, Acadia, Bristol-Myers Squibb, Corcept Therapeutics, Cyberonics, Cypress Bioscience, Eli Lilly, Entrepreneur's Fund, Forest, GlaxoSmithKline, H. Lundbeck, i3DLN, Janssen, Otsuka, Pfizer, Quintiles, UCB Pharma, and Wyeth-Ayerst; had received grant/research support from American Foundation for Suicide Prevention, AstraZeneca, Bristol-Myers Squibb, Forest, Janssen, National Alliance for Research on Schizophrenia and Depression (NARSAD),

National Institute of Mental Health, Pfizer, and Wyeth-Ayerst; was a member of the speakers bureau for Abbott, GlaxoSmithKline, Janssen, and Pfizer; was a stock shareholder of Acadia Pharmaceuticals, Corcept Therapeutics, Cypress Bioscience, and NovaDel Pharma; was on the Board of Directors of The American Foundation for Suicide Prevention, American Psychiatric Institute for Research and Education, George West Mental Health Foundation, NovaDel Pharma, and National Foundation for Mental Health; holds a patent for a method and devices for transdermal delivery of lithium (US 6,375,999) and for a method to estimate serotonin; had a provisional filing (April 2001) for a method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum; and had equity in Reevax, BMC-JR LLC, and CeNeRx. Currently, Dr. Nemeroff is supported by grants from the National Institutes of Health, NARSAD, and the American Foundation for Suicide Prevention.

REFERENCES

1. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. *J Clin Psychiatry* 1997;58(suppl 13):23–29
2. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? *Biol Psychiatry* 2003;53:640–648
3. Depression Guideline Panel: Clinical Practice Guideline 5: Depression in Primary Care, vol 2: Treatment of Major Depression. Rockville, Md: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993
4. Fawcett J, Barkin RL. Efficacy issues with antidepressants. *J Clin Psychiatry* 1997;58(suppl 6):32–39
5. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. *Arch Gen Psychiatry* 2004;61:669–680
6. Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. *Arch Gen Psychiatry* 2004;61:1042–1049
7. Trivedi MH, Rush AJ, Wisniewski SR, et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am J Psychiatry* 2006;163:28–40
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. *N Engl J Med* 2006;354:1231–1242
9. Trivedi MH, Fava M, Wisniewski SR, et al. STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. *N Engl J Med* 2006;354:1243–1252
10. Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA* 2003;289:3095–3105
11. Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. *J Clin Psychopharmacol* 2005;25:336–341
12. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. *J Clin Psychiatry* 2002;63:963–971
13. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. *J Clin Psychiatry* 2004;65:341–347
14. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. *J Clin Psychiatry* 1993;54:405–418
15. Nemeroff CB. Improving antidepressant adherence. *J Clin Psychiatry* 2003;64(suppl 18):25–30
16. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. *Eur Neuropsychopharmacol* 1999;9:83–91
17. Basco MR, Rush AJ. Compliance with pharmacotherapy in mood disorders. *Psychiatry Ann* 1995;25:269–279
18. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. *J Clin Psychopharmacol* 1994;14:230–240
19. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. *J Clin Psychiatry* 1999;60(suppl 22):7–11
20. Thase ME. Introduction: defining remission in patients treated with antidepressants. *J Clin Psychiatry* 1999;60(suppl 22):3–6
21. Rush AJ. The varied clinical presentations of major depressive disorder. *J Clin Psychiatry* 2007;68(suppl 8):4–10
22. Yates WR, Mitchell J, Rush AJ, et al. Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. *Gen Hosp Psychiatry* 2004;26:421–429
23. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national comorbidity sample. *Am J Psychiatry* 1994;151:979–986
24. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. *J Clin Psychopharmacol* 1994;14:419–423
25. Joffe RT, Levitt AJ, Sokolov ST, et al. Response to an open trial of a second SSRI in major depression. *J Clin Psychiatry* 1996;57:114–115
26. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. *J Clin Psychiatry* 1997;58:16–21
27. de Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. *J Clin Psychopharmacol* 1999;19:401–406
28. Fava M. Management of nonresponse and intolerance: switching strategies. *J Clin Psychiatry* 2000;61(suppl 2):10–12
29. Thase ME, Feighner JP, Lydiard RB. Citalopram treatment of fluoxetine nonresponders. *J Clin Psychiatry* 2001;62:683–687
30. Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. *J Clin Psychiatry* 2001;62:413–420
31. Fava M, McGrath PJ, Sheu WP. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. *J Clin Psychopharmacol* 2003;23:365–369
32. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. *Prog Neuropsychopharmacol Biol Psychiatry* 2002;26:1129–1134
33. Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine resistant major depressive disorder. *Ann Clin Psychiatry* 2003;15:17–22
34. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression, 1: non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. *Acta Psychiatr Scand* 1988;78:668–675
35. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression, 2: MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. *Acta Psychiatr Scand* 1988;78:676–683
36. Nolen WA, Haffmans PM, Bouvy PF, et al. Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. *J Affect Disord* 1993;28:189–197
37. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. *Br J Psychiatry* 1999;175:12–16
38. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. *Arch Gen Psychiatry* 2002;59:233–239
39. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. *Biol Psychiatry* 2001;50:345–350
40. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. *Neuropsychopharmacology* 1995;12:185–219
41. Nolen WA, van de Putte JJ, Dijken WA, et al. L-5HTP in depression resistant to re-uptake inhibitors: an open comparative study with tranylcypromine. *Br J Psychiatry* 1985;147:16–22
42. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, 3: efficacy of monoamine oxidase inhibitors. *J Clin Psychiatry* 1992;53:5–11
43. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine resistant recurrent depression, 4: a double-blind, cross-over study of tranylcypromine in anergic bipolar depression. *Am J Psychiatry* 1992;149:195–198
44. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. *Am J Psychiatry* 1993;150:118–123
45. Amsterdam JD. Use of high dose tranylcypromine in resistant depression. In: Amsterdam JD, ed. *Refractory Depression*. New York, NY: Raven Press, Ltd; 1991:123–130
46. Volz HP, Faltus F, Magyar I, et al. Brofaromine in treatment-resistant depressed patients—a comparative trial versus tranylcypromine. *J Affect Disord* 1994;30:209–217
47. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression: a retrospective study. *J Affect Disord* 2005;89:183–188
48. Birkenhager TK, van den Broek WW, Mulder PG, et al. Efficacy and

- tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. *J Clin Psychiatry* 2004; 65:1505–1510
49. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. *J Clin Psychiatry* 2000; 61:403–408
 50. de la Gándara J, Agüera L, Rojo JE, et al. Use of antidepressant combinations: which, when and why? results of a Spanish survey. *Acta Psychiatr Scand Suppl* 2005;32–36
 51. DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. *J Clin Psychopharmacol* 2003;23:27–30
 52. Rubio G, San L, Lopez-Munoz F, et al. Reboxetine adjunct for partial or nonresponders to antidepressant treatment. *J Affect Disord* 2004;81: 67–72
 53. Lam RW, Wan DD, Cohen NL, et al. Combining antidepressants for treatment-resistant depression: a review. *J Clin Psychiatry* 2002;63: 685–693
 54. Papakostas GI, Worthington JJ 3rd, Iosifescu DV, et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. *Depress Anxiety* 2006;23:178–181
 55. Poirier MF, Boyer P, Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. *Br J Psychiatry* 1999;175:12–16
 56. Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. *Arch Gen Psychiatry* 1996;53:842–848
 57. Altschuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? a review and meta-analysis of the literature. *Am J Psychiatry* 2001;158:1617–1622
 58. Bauer M, Forsthoef A, Baethge C, et al. Lithium augmentation therapy in refractory depression—update 2002. *Eur Arch Psychiatry Clin Neurosci* 2003;253:132–139
 59. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. *Am J Psychiatry* 2006;163:1519–1530
 60. Moreno F, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. *J Clin Psychiatry* 1997;58:437–439
 61. Perez V, Soler J, Puigdemont D, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitor. *Arch Gen Psychiatry* 1999;56: 375–379
 62. Perry EB, Berman RM, Sanacora G, et al. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. *J Clin Psychiatry* 2004;65: 238–243
 63. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. *Am J Psychiatry* 2001; 158:131–134
 64. Sharpley AL, Bhagwagar Z, Hafizi S, et al. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. *J Clin Psychiatry* 2003;64:192–196
 65. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. *J Clin Psychiatry* 2005;66:1289–1297
 66. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. *J Clin Psychiatry* 2005;66:1216–1220
 67. Zink M. Augmentation of olanzapine in treatment-resistant schizophrenia. *J Psychiatry Neurosci* 2005;30:409–415
 68. Nemeroff CB, Gharabawi GM, Canuso CM, et al. Augmentation with risperidone in chronic resistant depression: a double-blind placebo-controlled maintenance trial. *Neuropsychopharmacol* 2004;29:51–59
 69. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. *J Clin Psychiatry* 2005;66(suppl 8):13–21
 70. Rapaport MH, Canuso CM, Rouillon F, et al. Treatment augmentation with risperidone for patients with resistant depression. Presented at the 157th annual meeting of the American Psychiatric Association; May 1–6, 2004; New York, NY
 71. Dunner DL, Amsterdam JD, Shelton RC, et al. Adjunctive ziprasidone in treatment-resistant depression: a randomized, double-blind, 8-week, pilot study. Presented at the 43rd annual meeting of the American College of Neuropsychopharmacology; Dec 12–16, 2004; San Juan, Puerto Rico
 72. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. *Neuropsychopharmacology* 2006;31:2505–2513
 73. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. *J Clin Psychiatry* 2003;64:403–407
 74. Gutierrez RL, McKercher RM, Galea J, et al. Lamotrigine augmentation strategy for patients with treatment-resistant depression. *CNS Spectr* 2005;10:800–805
 75. Fawcett J, Kravitz HM, Zajecka J, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. *J Clin Psychopharmacol* 1991;11:127–132
 76. Stoll AL, Pillay SS, Diamond L, et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. *J Clin Psychiatry* 1996;57:72–76
 77. Lavretsky H, Kim MD, Kumar A, et al. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. *J Clin Psychiatry* 2003;64:1410–1414
 78. Bader G, Hawley JM, Short DD. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. *J Clin Psychopharmacol* 1998;18:255–256
 79. Fawcett J, Busch KA. Stimulants in psychiatry. In: Schatzberg AF, Nemeroff CB, eds. *Essentials of Clinical Psychopharmacology*. Washington, DC: American Psychiatric Association Press; 2001
 80. Menza MA, Kaufman KR, Castellanos AM. Modafinil augmentation of antidepressant treatment in depression. *J Clin Psychiatry* 2000;61:378–381
 81. DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. *J Clin Psychiatry* 2003;64:1057–1064
 82. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. *J Clin Psychiatry* 2005;66:85–93
 83. Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. *CNS Spectr* 2006;11: 93–102
 84. DeBattista C, Lembke A, Solvason HB, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. *J Clin Psychopharmacol* 2004;24:87–90
 85. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. *Am J Psychiatry* 2004;161: 564–566
 86. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. *Depress Anxiety* 2000;11:58–65
 87. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. *Ann Clin Psychiatry* 2000;12:137–140
 88. Lattanzi L, Dell’Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. *Bipolar Disord* 2002;4:307–314
 89. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. *Biol Psychiatry* 2004;56:54–60
 90. Janicak PG, Davis JM, Gibbons RD, et al. Efficacy of ECT: a meta-analysis. *Am J Psychiatry* 1985;142:297–307
 91. The UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet* 2003;361:799–808
 92. Pagnin D, de Queiroz V, Pini S, et al. Efficacy of ECT in depression: a meta-analytic review. *J ECT* 2004;20:13–20
 93. Folkerts HW, Michael N, Tolle R, et al. Electroconvulsive therapy vs paroxetine in treatment-resistant depression—a randomized study. *Acta Psychiatr Scand* 1997;96:334–342
 94. George MS, Sackeim HA, Rush AJ, et al. Vagus nerve stimulation: a new tool for brain research and therapy. *Biol Psychiatry* 2000;47:287–295
 95. Chae JH, Nahas Z, Lomarev M, et al. A review of functional neuroimaging studies of vagus nerve stimulation (VNS). *J Psychiatr Res* 2003;37: 443–455
 96. Nemeroff CB, Mayberg HS, Krahl SE, et al. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. *Neuropsychopharmacology* 2006;31:1345–1355
 97. Carpenter LL, Moreno FA, Kling MA, et al. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients.

- Biol Psychiatry 2004;56:418–426
98. Papakostas GI. Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder. *Essent Psychopharmacol* 2005;6:209–220
 99. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. *Neuropsychopharmacology* 2001;25:713–728
 100. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. *Biol Psychiatry* 2005;58:347–354
 101. Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. *Biol Psychiatry* 2005;58:355–363
 102. Holtzheimer PE 3rd, Russo J, Avery DH. A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. *Psychopharmacol Bull* 2001;35:149–169
 103. Rossini D, Lucca A, Zanardi R, et al. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. *Psychiatry Res* 2005;137:1–10
 104. Fitzgerald PB, Benitez J, de Castella A, et al. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. *Am J Psychiatry* 2006;163:88–94
 105. Avery DH, Holtzheimer PE 3rd, Fawaz W, et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. *Biol Psychiatry* 2006;59:187–194
 106. O'Reardon JP. Repetitive transcranial magnetic stimulation at 10 Hz in the treatment of pharmacoresistant major depression: results from a controlled multicenter clinical trial. Platform presentation at the 139th annual meeting of the American Psychiatric Association; May 23, 2006; Toronto, Canada
 107. Kosel M, Frick C, Lisanby SH, et al. Magnetic seizure therapy improves mood in refractory major depression. *Neuropsychopharmacology* 2003;28:2045–2048
 108. Carpenter LL. Neurostimulation in resistant depression. *J Psychopharmacol* 2006;20:35–40
 109. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. *Neuron* 2005;45:651–660
 110. Thase ME, Friedman ES, Howland RH. Management of treatment-resistant depression: psychotherapeutic perspectives. *J Clin Psychiatry* 2001;62(suppl 18):18–24
 111. Thase ME. Pharmacologic strategies for treatment-resistant depression. *Psychiatr Ann* 2005;35:970–978